VRDN - NASDAQ
Viridian Therapeutics, Inc.
$16.92
+6.6%Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotViridian Therapeutics, Inc. Management Team
Mr. Anthony Casciano
Chief Commercial Officer
Mr. Stephen F. Mahoney J.D., MBA
Chief Executive Officer, President & Director
Compensation
$652,704
Mr. Seth Harmon
Chief Financial Officer
Compensation
$552,467
Ms. Melissa Manno
Chief Human Resources Officer
Ms. Jennifer Tousignant J.D.
Chief Legal Officer
Compensation
$611,951
Mr. Thomas W. Beetham J.D., MBA
Chief Operating Officer
Compensation
$517,000
Dr. Eric N. Olson Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael R. Bristow M.D., Ph.D.
Co-Founder & Member of the Scientific Advisory Board
Mr. Vahe Bedian Ph.D.
Co-Founder & Scientific Advisor
Dr. Marvin H. Caruthers Ph.D.
Co-Founder & Scientific Advisory Board Member
Viridian Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $31.99M and sold $71K worth of VRDN shares, resulting in $31.92M of net buying activity.
3 Months
1.2M
20.00M
0
0.00
+20.0M
+$20.00M
3-6 Months
0
0.00
2.3K
70.80K
-71K
-$71K
6-9 Months
454.5K
10.00M
0
0.00
+10.0M
+$10.00M
9-12 Months
140.1K
1.99M
0
0.00
+2.0M
+$1.99M
Top Buyers
Fairmount Funds Management Llc
Director, 10 Percent Owner:
$30.17M
Morris Arlene
Director
$304K
Ajer Jeffrey Robert
Director
$304K
Gheuens Sarah
Director
$304K
Moses Jennifer K.
Director
$304K
Top Sellers
Tousignant Jennifer
Officer: Chief Legal Officer
$71K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $31.92M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
VRDN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | June 02, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 20, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 17, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 14, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | April 30, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | December 14, 2020 | December 31, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | April 10, 2020 | April 10, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | May 03, 2019 | May 03, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | May 15, 2018 | June 27, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.